Sudden Infant Death Syndrome (SIDS) Cell Models for Research

Sudden Infant Death Syndrome (SIDS) is the sudden, unexplained death of an infant under one year of age. According to the World Health Organization (WHO), SIDS remains a leading cause of post-neonatal infant mortality in developed countries, with an incidence of approximately 0.2-1.5 per 1,000 live births. The exact cause is unknown, but risk factors include prone sleeping, maternal smoking, and prematurity. The National Cancer Institute (NCI) does not track SIDS as it is not a cancer, but the Centers for Disease Control and Prevention (CDC) reports about 3,500 sudden unexpected infant deaths (SUID) annually in the US, of which about 1,500 are attributed to SIDS. The lack of a clear pathophysiological mechanism hampers prevention and intervention strategies.

SIDS is a complex, multifactorial disorder involving genetic, environmental, and developmental factors. It is an ideal model for studying autonomic nervous system dysfunction, cardiac arrhythmias, and neurotransmitter imbalances. Public datasets from the NICHD and other repositories provide genomic and transcriptomic data from SIDS cases. Open questions include the role of genetic variants in serotonin receptors, cardiac ion channels, and brainstem development. Gene-edited cell models can help dissect these pathways and identify potential biomarkers.

While SIDS is not a cancer, it involves abnormal development and function. Key pathways include:

• • Serotonergic signaling: Defects in the raphe nuclei and serotonin transporter (SLC6A4) are implicated.
• • Cardiac ion channel dysfunction: Mutations in genes like SCN5A, KCNQ1, and KCNH2 can cause arrhythmias.
• • Autonomic nervous system regulation: Imbalance in sympathetic/parasympathetic tone.
• • Inflammatory and immune responses: Abnormal cytokine profiles may contribute to vulnerability.

Data from ClinVar and literature.

Key networks include:

• • Serotonergic network: TPH2, HTR1A, HTR2A, SLC6A4.
• • Cardiac ion channel network: SCN5A, KCNQ1, KCNH2, KCNE1.
• • Autonomic network: PHOX2B, RET, EDN3.
• • Inflammatory network: IL-6, TNF-alpha, IL-1beta.

Organoids derived from induced pluripotent stem cells (iPSCs) can model brainstem development and are useful for studying SIDS-related genes.

Animal models for SIDS include:

• • Genetically engineered mouse models (GEMMs) with knockouts of serotonin-related genes (e.g., Tph2, Slc6a4).
• • Rat models with induced hypoxia or hypercapnia to mimic autonomic dysfunction.
• • Rabbit models for cardiac arrhythmia studies.
• • Zebrafish models for cardiac and neuronal development.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific mutations associated with SIDS. For example:

• • SLC6A4 knockout in SH-SY5Y cells to study serotonin reuptake.
• • SCN5A knock-in with a pathogenic variant to model cardiac arrhythmia.
• • PHOX2B polyalanine repeat expansion knock-in in iPSC-derived neurons.

These models are commercially available and sequence-verified, accelerating research without the need for in-house editing.

Knockout and knock-in lines allow functional validation of candidate genes. For example, SLC6A4 knockout in SH-SY5Y cells demonstrates altered serotonin uptake, confirming its role. Similarly, SCN5A knock-in can be used to study sodium current abnormalities.

Isogenic pairs (wild-type vs. mutant) are used to screen drugs that modulate serotonin signaling or cardiac ion channels. For instance, testing SSRIs on SLC6A4 knockout cells can reveal off-target effects. Resistance to drugs can be modeled by introducing resistance mutations.

CRISPR synthetic lethality screens can identify genes that, when knocked out, are lethal only in SIDS-mutant cells. This can reveal potential therapeutic targets and biomarkers.